이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Extrawell Pharmaceutical Holdings 미래 성장

Future 기준 확인 0/6

현재 Extrawell Pharmaceutical Holdings 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Pharmaceuticals 수익 성장	10.7%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Mar 18

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

Dec 01

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Aug 04

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Mar 15

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Aug 20

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Extrawell Pharmaceutical Holdings 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

SEHK:858 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (HKD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2024	59	-163	N/A	N/A	N/A
12/31/2023	64	-159	N/A	N/A	N/A
9/30/2023	69	-154	-8	-2	N/A
6/30/2023	71	-13	-7	0	N/A
3/31/2023	73	129	-5	1	N/A
12/31/2022	69	109	-8	0	N/A
9/30/2022	65	88	-11	-2	N/A
6/30/2022	69	109	-11	-2	N/A
3/31/2022	74	131	-11	-2	N/A
12/31/2021	80	12	-9	-3	N/A
9/30/2021	86	-107	-6	-5	N/A
6/30/2021	82	-114	-4	-3	N/A
3/31/2021	79	-121	-2	-1	N/A
12/31/2020	76	6	-3	-3	N/A
9/30/2020	74	133	-5	-5	N/A
6/30/2020	76	108	-9	-9	N/A
3/31/2020	78	83	-13	-13	N/A
12/31/2019	81	73	-14	-13	N/A
9/30/2019	85	63	-14	-13	N/A
6/30/2019	87	63	-15	-14	N/A
3/31/2019	89	64	-17	-15	N/A
12/31/2018	86	51	-16	-15	N/A
9/30/2018	83	39	-15	-15	N/A
6/30/2018	85	34	-10	-10	N/A
3/31/2018	86	30	-5	-5	N/A
12/31/2017	88	32	N/A	-5	N/A
9/30/2017	91	34	N/A	-4	N/A
6/30/2017	100	27	N/A	1	N/A
3/31/2017	108	21	N/A	5	N/A
12/31/2016	116	46	N/A	19	N/A
9/30/2016	125	71	N/A	32	N/A
6/30/2016	133	52	N/A	19	N/A
3/31/2016	142	33	N/A	6	N/A
9/30/2015	136	-81	N/A	-34	N/A
6/30/2015	132	-63	N/A	-29	N/A
3/31/2015	129	-44	N/A	-23	N/A
9/30/2014	155	13	N/A	62	N/A
6/30/2014	153	13	N/A	63	N/A
3/31/2014	151	14	N/A	64	N/A
12/31/2013	144	11	N/A	38	N/A
9/30/2013	138	9	N/A	-7	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 858 의 예상 수익 증가율이 절약률( 2.2% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: 858 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 858 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: 858 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 858 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 858 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Extrawell Pharmaceutical Holdings 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023

Extrawell Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 September 2022

Extrawell Pharmaceutical Holdings Limited Provides Earnings Guidance for the Year Ended March 31, 2022

Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended March 31, 2021

Recent updates

Full year 2024 earnings released: HK$0.068 loss per share (vs HK$0.054 profit in FY 2023)

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Jun 28, 2024

Extrawell Pharmaceutical Holdings Limited Announces Board and Committee Changes

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

New major risk - Share price stability

New major risk - Market cap size

First half 2024 earnings released: HK$0.099 loss per share (vs HK$0.019 profit in 1H 2023)

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

New major risk - Revenue and earnings growth

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Nov 29, 2023

New minor risk - Share price stability

Full year 2023 earnings released: EPS: HK$0.054 (vs HK$0.055 in FY 2022)

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 25, 2023

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: HK$0.054 (vs HK$0.055 in FY 2022)

New minor risk - Financial data availability

Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

Extrawell Pharmaceutical Holdings Limited Announces Demise of Mr. Xue Jing Lun, Independent Non-Executive Director, and A Member of Each of the Audit Committee, Remuneration Committee and Nomination Committee

First half 2023 earnings released: EPS: HK$0.019 (vs HK$0.037 in 1H 2022)

Extrawell Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 September 2022

Less than half of directors are independent

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Nov 29, 2022

Extrawell Pharmaceutical Holdings Limited Announces Management Changes

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Full year 2022 earnings released: EPS: HK$0.055 (vs HK$0.051 loss in FY 2021)

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 30, 2022

Full year 2022 earnings released

Extrawell Pharmaceutical Holdings Limited Provides Earnings Guidance for the Year Ended March 31, 2022

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Full year 2021 earnings released: HK$0.051 loss per share (vs HK$0.035 profit in FY 2020)

Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended March 31, 2021

First half 2021 earnings released: EPS HK$0.031

First half 2021 earnings released: EPS HK$0.031

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2021 Results on Nov 27, 2020

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견